Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-08-23

Clinical Trial Update: Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 trial update of CD 2027 spray evaluated for efficacy and safety in plaque-type psoriasis; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CD 2027 spray (CD 2027 spray)

Snippet

Sponsor: Galderma R&D | Conditions: Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2022-08-23